L. Sequist

Pulmonary and Respiratory Medicine · 2007–2025

A researcher in the Science corpus: 27 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Pulmonary and Respiratory Medicine — 326 citations into it

Whom L. Sequist trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. L. Tanoue
2. Vincent A. Miller
3. William Pao
4. J. Engelman

Who trusts L. Sequist overall

1. Shang-Gin Wu
2. Jin-Yuan Shih
3. J. Engelman
4. B. Chan

Papers from L. Sequist's perspective

Ordered by how strongly the researchers L. Sequist trusts endorse each paper. Same corpus, a different order for every researcher.

1. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (Science)
2. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. (New England Journal of Medicine)
3. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
4. Pembrolizumab for the treatment of non-small-cell lung cancer. (New England Journal of Medicine)
5. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer… (Journal of the National Cancer Institute)
6. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. (Cancer Cell)
7. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients (Nature)
8. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling (Science)
9. Detection of mutations in EGFR in circulating lung-cancer cells. (New England Journal of Medicine)
10. Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer (New England Journal of Medicine)

Their papers

• Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition (2013) — 2,310 citations
• Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells (2013) — 1,059 citations
• Isolation of rare circulating tumour cells in cancer patients by microchip technology (2007) — 3,550 citations
• Isolation of circulating tumor cells using a microvortex-generating herringbone-chip (2010) — 1,612 citations
• Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs (2014) — 1,641 citations
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors (2011) — 3,396 citations
• Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition (2016) — 897 citations
• Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers (2012) — 1,322 citations
• RNA-Seq of Single Prostate CTCs Implicates Noncanonical Wnt Signaling in Antiandrogen Resistance (2015) — 683 citations
• Rociletinib in EGFR-mutated non-small-cell lung cancer. (2015) — 627 citations
• Eradicating Drug Tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy (2025)
• Lung cancer (2021) — 1,036 citations
• Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. (2018) — 635 citations
• Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study (2016) — 1,306 citations
• Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer (2016) — 1,054 citations
• EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer (NSCLC): A Retrospective Analysis (2016) — 1,124 citations
• Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. (2015) — 1,453 citations
• Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. (2015) — 1,081 citations
• Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. (2015) — 929 citations
• Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin (2015) — 866 citations